Showing 21 - 40 results of 120,214 for search '(( 5 ((((nm decrease) OR (a decrease))) OR (nn decrease)) ) OR ( 2 e decrease ))', query time: 1.70s Refine Results
  1. 21

    HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching. by Michael Anthony Ruiz (726055)

    Published 2015
    “…However, transfection of SUZ12 siRNA significantly reduced endothelial branching compared to HG+control siRNA. [NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”
  2. 22
  3. 23

    Decreased IL-7 responses in ICL. by Florence Bugault (278171)

    Published 2013
    “…A dose dependent response is observed, with a higher pSTAT5 expression at high IL-7 dose (2 nM) than at low IL-7 dose (20 pM). …”
  4. 24
  5. 25

    Vasopressin decreases EPSPs in CA2 after LTP induction. by Magda Chafai (295116)

    Published 2013
    “…</i> time showing that AVP did not affect the basal EC LIII-CA2 EPSP recorded before HFS stimulation. E) Left, Typical graph of the fEPSP evoked by Schaffer collaterals stimulation and recorded in a CA1 pyramidal neuron (SC-CA1); AVP did not affect the amplitude of the LTP-potentiated EPSP , as shown on the average graph (Right, n = 4).…”
  6. 26
  7. 27
  8. 28
  9. 29

    The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

    Published 2019
    “…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40

    CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line. by Mariam El-Ashmawy (678638)

    Published 2014
    “…Immortalized HBECs with (A) lenti-<i>KRas</i><sup>V12</sup>, (B) lenti-<i>KRas</i><sup>V12</sup> and sh<i>p53</i> knockdown, and (C) lenti-<i>KRas</i><sup>V12</sup>, sh<i>p53</i>, and <i>myc</i> overexpression. …”